From: TheStreet By: Tony Owusu Biogen shares were falling in trading Friday after analysts at Piper Jaffray downgraded the stock to neutral from overweight on concerns about competitive pressures for the suite of the company's multiple sclerosis treatments. The firm also lowered its price target to $250 from $280 per share. Shares fell in trading by 1.4% to $236.36. Piper Jaffray analyst Christopher Raymond cited new neurologist survey data from Spherix Global Insights that "spells bad news for both Tecfidera and Tysabri in the near and long term." The company's Tecfidera multiple sclerosis [...]
From: Barron's By: Josh Nathan-Kazis Biogen stock was slipping on Friday morning as one analyst warned that the company’s drug for multiple sclerosis could be losing ground to new competitors. Citing data from a proprietary survey of doctors treating MS patients, PiperJaffray analyst Christopher Raymond outlined threats to the market share of Biogen’s Tysabri from Novartis’ (NVS) newly-approved MS drug Mayzent and Roche’s (CH:ROG) drug Ocrevus...(read more).
About 15 disease-modifying therapies (DMTs) are available to treat MS these days. So, choosing which to use can be daunting. I’ve been treated with four DMTs since I was first prescribed Avonex (interferon beta-1a) back in 1996. Each time I’ve switched treatments, my neurologist has suggested a number of DMTs she thought would be best for me. But she left the final decision in my hands.
From: Lupus News Today By: Iqra Mumal Patients participating in Phase 3 clinical trials testing new therapies for systemic lupus erythematosus (SLE) are not necessarily representative of real-world patient populations, according to a new report. Even if the therapies being investigated reach the market, real-world experiences may differ significantly from trial results because many lupus patients are not eligible to participate in studies due to exclusion criteria, the report says....(read more).